Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), tells Proactive Investors the 'cream' formulation of its SkinBiotix technology has passed effectiveness studies in models of skin.
The cream formulation will now undergo further testing for stability in the coming weeks.
Meet 360 Blockchain Inc, Alterola Biotech, Inc, LGC Capital Ltd and BlowFish Technologies at our event,New York, 18 April 2018.Register here >>